Triazolopyridine ethers as potent, orally active mGlu2 positive allosteric modulators for treating schizophrenia
摘要:
Triazolopyridine ethers with mGlu(2) positive allosteric modulator (PAM) activity are disclosed. The synthesis, in vitro activity, and metabolic stability data for a series of analogs is provided. The effort resulted in the discovery of a potent, selective, and brain penetrant lead molecule BMT-133218 ((+)-7m). After oral administration at 10 mg/kg, BMT-133218 demonstrated full reversal of PCP-stimulated locomotor activity and prevented MK-801-induced working memory deficits in separate mouse models. Also, reversal of impairments in executive function were observed in rat set-shifting studies at 3 and 10 mg/kg (p.o.). Extensive plasma protein binding as the result of high lipophilicity likely limited activity at lower doses. Optimized triazolopyridine ethers offer utility as mG1u(2) PAMs for the treatment of schizophrenia and merit further preclinical investigation. (C) 2016 Elsevier Ltd. All rights reserved.
[EN] MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES DE L'ACÉTYLCHOLINE M1
申请人:PIPELINE THERAPEUTICS INC
公开号:WO2021071843A1
公开(公告)日:2021-04-15
Provided herein, inter alia, are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
[EN] PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] DÉRIVÉS DE L'ACIDE PYRIDIN-3-YL-ACÉTIQUE UTILISÉS COMME INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
申请人:VIIV HEALTHCARE UK (NO 5) LTD
公开号:WO2017006260A1
公开(公告)日:2017-01-12
Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
Rhodium‐Catalyzed Enantioselective Silylation of Cyclopropyl C−H Bonds
作者:Taegyo Lee、John F. Hartwig
DOI:10.1002/anie.201603153
日期:2016.7.18
Hydrosilyl ethers, generated in situ by the dehydrogenative silylation of cyclopropylmethanols with diethylsilane, undergo asymmetric, intramolecular silylation of cyclopropyl C−Hbonds in high yields and with high enantiomeric excesses in the presence of a rhodium catalyst derived from a rhodium precursor and the bisphosphine (S)‐DTBM‐SEGPHOS. The resulting enantioenriched oxasilolanes are suitable
氢硅烷基醚是通过环丙基甲醇与二乙基硅烷的脱氢硅烷化原位生成的,在源自铑前体和双膦的铑催化剂存在下,以高收率和高对映体过量进行环丙基CH键的不对称分子内硅烷化( S )-DTBM-SEGPHOS。所得的对映体富集的氧杂硅氧烷是 Tamao-Fleming 氧化形成环丙醇的合适底物,同时保留了 C−H 甲硅烷基化的ee值。初步的机制数据表明,C−H 裂解可能是转换限制和对映选择性决定步骤。
Heterocyclic compounds
申请人:Eli Lilly and Company
公开号:US06117883A1
公开(公告)日:2000-09-12
The present invention provides heterocyclic compounds which are useful for modulating a muscarinic receptor.
TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20160237081A1
公开(公告)日:2016-08-18
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.